PROSTATE VAPORIZATION BY DIODE LASER FOR PATIENTS WITH BENIGN PROSTATIC ENLARGEMENT
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i12.29572Keywords:
Benign prostatic hyperplasia, Digital rectal examination, prostate-specific antigen, International prostate symptom scoreAbstract
Objectives: The objectives of this study were to study the efficacy of diode laser prostatectomy in patients infected with benign prostatic enlargement.
Methods: A total of 62 men were included in our prospective clinical study from August 2017 to January 2018. The size of their prostates (ml) was ranged from 38 to 65, digital rectal examination for all patients was revealed the features of benign prostatic enlargement, prostate-specific antigen was ranged from 0.3 to 14 ng/ml, underwent laser prostatectomy (Diode laser).
Results: The study included 62 men with 67.82±7.57 years. After the operation, the median maximum flow rate (Qmax) was increased 11–22 ml/s and the increment was highly significant (p<0.001), and median international prostate symptom score was highly significantly reduced from 19 to 10 (p<0.001). In addition, median residual volume was highly significantly reduced from 169.5 to 77 ml (p<0.001). Mean duration of operation was 67.82±7.57 min. The duration of catheterization with a mean of 1.16±0.45 days. Most patients required only 1 day of hospital stay postoperatively. No one developed post-operative bleeding, erectile dysfunction was reported in a single patient (1.6%), urinary incontinence in one patient (1.6%), and urinary tract infection was the most frequent post-operative complication being reported in 11.3%.
Conclusion: Diode laser for the treatment of prostate is easily applicable, cheap and provides good ablation with low morbidity.
Downloads
References
AUA practice Guidelines Committee. AUA guidelines on management of benign prostatic hyperplasia. Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170:530-47.
Lee NG, Xue H, Lerner LB. Trends and attitudes in surgical management of benign prostatic hyperplasia. Can J Urol 2012;19:6170-5.
Gravas S, Bachmann A, Reich O, Roehrborn CG, Gilling PJ, De La Rosette J. Critical review of lasers in benign prostatic hyperplasia (BPH). BJU Int 2011;107:1030-43.
Einstein A. Zur Quantentheorie der Strahlung. [On the Quantum Mechanics of Radiation]. Phys Z 1917;18:121-8.
Al-Grawi ED, Al-Awsi GR. Expression of CDKN2A (P16/Ink4a) among colorectal cancer patients: A cohort study. J Pharm Sci Res 2018;10:5.
Hofstetter A, Alarcon-Hofstetter A. Treatment of prostatic tumors with interstitial thermocoagulation with neodymium-YAG. (A new treatment in minimally invasive surgery). Arch Esp Urol 1993;46:317-9.
Costello AJ, Bowsher WG, Bolton DM, Braslis KG, BurtJ. Laser ablation of the prostate in patients with benign prostatic hypertrophy. Br J Urol 1992;69:603-8.
Malek RS, Barrett DM, Kuntzman RS. High-power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 h later. Urology 1998;51:254-6.
Reich O, Bachmann A, Schneede P, Zaak D, Sulser T, Hofstetter A.Experimental comparison of high power (80 W) potassium titanyl phosphate laser vaporization and transurethral resection of the prostate. J Urol 2004;171:2502-4.
Reich O, Bachmann A, Siebels M, Hofstetter A, Stief CG, Sulser T. High power (80 W) potassium-titanylphosphate laser vaporization of the prostate in 66 high risk patients. J Urol 2005;173:158-60.
Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 ml: A short term prospective randomized trial. Urol 2008;71:247-51.
Zhao Y, Liu C, Zhou G, Yu C, Zhang Y, Ouyang Y. A retrospective evaluation of benign prostatic hyperplasia treatment by transurethral vaporization using a 1470 nm laser. Photomed Laser Surg 2013;31:626 9.
AL-Nashi AP, Raheem AA, Lateef Gr. Isolate and diagnose the bacteria present in the hospital in the city of Diwaniyah and the statement of the mechanisms to control the use of antibiotics and antiseptics. Al-Qadisiyah J Pure Sci 2013;18:11-20.
Hamann MF, Naumann CM, Seif C, van der Horst C, Jünemann KP, Braun PM. Functional outcome following photoselectivevaporisation of the prostate (PVP): Urodynamic findings within 12 months follow-up. Eur Urol 2008;54:902-7.
Gilling PJ, Kennett KM, Fraundorfer MR. Holmium laser enucleation of the prostate for glands larger than 100 g: An endourologic alternative to open prostatectomy. J Endourol 2000;14:529-31.
Reich O. Editorial comment on: Functional outcome following photoselectivevaporisation of the prostate (PVP): Urodynamic findings within 12 months followup. Eur Urol 2008;54:908.
Shamran AR, Shaker ZH, Al-Awsi GR, Khamis AS, Tolaifeh ZA, Jameel Z I. Rapd-PCR is a good DNA fingerprinting technique to detect phylogenetic relationships among Staphylococcus aureus isolated from different sources in Hilla city, Iraq. Biochem Cell Arch 2018;18:1157 61.
Erol A, Cam K, Tekin A, Memik O, Coban S, Ozer Y. High power diode laser vaporization of the prostate: Preliminary results for benign prostatic hyperplasia. J Urol 2009;182:1078-82.
Hendrika Y, Reveny J, Sumaiyah S. Formulation and in vitro evaluation of gastroretentive floating beads of amoxicillin using pectin from banana peel (Musa balbisiana AB). Asian J Pharm Clin Res 2018;11:72-7.
Gowda S, Patil N, Kotian R. Hypertrophic cardiomyopathy with partial anomalous pulmonary venous connection and atrial septal defect: A rare presentation. Asian J Pharm Clin Res 2017;10:5-7.
Thadiboina M, Adithya S, Vadivel K. Drug utilisation review in postoperativepatients in obstetrics-gynaecology and surgical gastroenterology departments-a retrospectve study. Int J Pharm Pharm Sci 2018;10:11-5.
Mandpe P, Prabhakar B. Pathophysiology, mechanism and management of overactive bladder syndrome - A review. Int J Pharm Pharm Sci 2018;10:1-3.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
